NCT00259740View on ClinicalTrials.gov

Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

August 31, 2007

Study Completion Date

December 31, 2011

Conditions

Relapsed or Plateau-Phase Multiple Myeloma

Interventions

DRUG

DENOSUMAB

120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.